Study: Effective vaccine response among young By WANG XIAOYU | China Daily | Updated: 2021-07-03 07:50 A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd, in Beijing, March 16, 2020. [Photo/Xinhua] The domestic COVID-19 vaccine developed by Sinovac Biotech is safe and can elicit a strong antibody response in people aged 3 to 17 in early and mid-stage clinical trials, according to a study published recently in a medical journal. The study is the world's first that examines the safety and protection effects of a COVID-19 vaccine for children as young as 3 years old. It also came as the spread of highly transmissible variants worldwide has prompted calls for accelerating mass immunization, and more countries are considering expanding the use of vaccines to cover young people, including China.